Molecular Mechanisms of Fungal Pathogen Host Interactions (ImResFun)

Project leader

Project Details

Start date: 01/10/2013
End date: 30/09/2017
Funding: 3591515 EUR


ImResFun shall provide state-of-the-art training in infectious disease research and medical immunology targeting the mostcommon human fungal pathogens, the opportunistic Candida species. The key objectives of ImResFun are: (i) to understandhow immune cells and infected organs respond to invasion by Candida spp, (ii) to decipher host-defense mechanismsmediating pathogen elimination, and (iii) to identify genetic networks driving the dynamics of host-pathogen interplay.ImResFun will exploit cutting-edge technologies to unravel the basic mechanisms of fungal pathogenesis and host immunity,and to improve diagnosis and identify novel biomarkers of infection. Importantly, ImResFun will translate research into clinicalpractice and identify potential targets for antifungal drug discovery. ImResFun has seven WPs. In addition to coordination(WP7), research will cover molecular mechanisms of host-pathogen interactions using dual-system infection biology invitro and in vivo (WP1), clinical patient setting and age-related infections (WP2), chemical biology and antifungal drugdevelopment (WP3), and bioinformatics and genome-wide data analysis (WP4). A compulsory and tailor-made practicalcourse (WP5) and complementary skills (WP6) program will boost hypothesis-driven projects. Meaningful exposure to theprivate sector is ensured by extensive secondments of all ESRs/ERs. The resulting reciprocal technology transfer will bebeneficial for both SMEs and ESR/ER hosts and sustain collaborations among partners. ImResFun will use personalizedcareer development plans for each ESR/ER to train entrepreneurial scientists capable of translating frontier researchinto clinical practice, biotechnology and drug discovery. Taken together, ImResFun offers a best-practice example forinterdisciplinary, intersectorial and supradisciplinary training in understanding the immunology of microbial infectiousdiseases, since most approaches are amenable to other microbial pathogens.

External Partners

Last updated on 2017-22-03 at 07:13